Steven Richards

Company: Ambagon Therapeutics

Job title: Vice President Chemistry

Seminars:

Development of Novel Therapeutics via Stabilization of 14-3-3: Client Protein Protein Interactions 3:30 pm

Regulating the activity of phosphorylated client proteins, many of which are “undruggable”, through 14-3-3, a ubiquitously expressed hub protein Binding exclusively to disordered regions of these clients creating an ordered binary complex which can be targeted by small molecule stabilizers Developing small molecule therapeutics that bind the composite 14-3-3:client protein surface to drug the undruggableRead more

day: Post-Conference Focus Day: Next Generation TPD